JP2013517307A5 - - Google Patents

Download PDF

Info

Publication number
JP2013517307A5
JP2013517307A5 JP2012549249A JP2012549249A JP2013517307A5 JP 2013517307 A5 JP2013517307 A5 JP 2013517307A5 JP 2012549249 A JP2012549249 A JP 2012549249A JP 2012549249 A JP2012549249 A JP 2012549249A JP 2013517307 A5 JP2013517307 A5 JP 2013517307A5
Authority
JP
Japan
Prior art keywords
lys
ser
arg
glu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012549249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517307A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2011/050018 external-priority patent/WO2011088837A1/en
Publication of JP2013517307A publication Critical patent/JP2013517307A/ja
Publication of JP2013517307A5 publication Critical patent/JP2013517307A5/ja
Withdrawn legal-status Critical Current

Links

JP2012549249A 2010-01-20 2011-01-20 心臓病の処置 Withdrawn JP2013517307A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29665710P 2010-01-20 2010-01-20
US61/296,657 2010-01-20
PCT/DK2011/050018 WO2011088837A1 (en) 2010-01-20 2011-01-20 Treatment of cardiac conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016074097A Division JP6200025B2 (ja) 2010-01-20 2016-04-01 心臓病の処置

Publications (2)

Publication Number Publication Date
JP2013517307A JP2013517307A (ja) 2013-05-16
JP2013517307A5 true JP2013517307A5 (enExample) 2014-03-13

Family

ID=43928934

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012549249A Withdrawn JP2013517307A (ja) 2010-01-20 2011-01-20 心臓病の処置
JP2016074097A Active JP6200025B2 (ja) 2010-01-20 2016-04-01 心臓病の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016074097A Active JP6200025B2 (ja) 2010-01-20 2016-04-01 心臓病の処置

Country Status (15)

Country Link
US (1) US20130157953A1 (enExample)
EP (1) EP2525809B1 (enExample)
JP (2) JP2013517307A (enExample)
KR (1) KR20120128129A (enExample)
CN (1) CN102892425A (enExample)
AU (1) AU2011206979B2 (enExample)
BR (1) BR112012018104A2 (enExample)
CA (1) CA2786934A1 (enExample)
CL (1) CL2012002037A1 (enExample)
EA (1) EA026384B1 (enExample)
IL (1) IL220876A0 (enExample)
MX (1) MX342409B (enExample)
NZ (1) NZ601167A (enExample)
PH (1) PH12012501494A1 (enExample)
WO (1) WO2011088837A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5635529B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
NZ593813A (en) 2008-12-15 2013-02-22 Zealand Pharma As Glucagon analogues
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
SG184988A1 (en) 2010-04-27 2012-11-29 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
AR081975A1 (es) * 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
EP2585482B1 (en) * 2010-06-24 2019-03-27 Zealand Pharma A/S Glucagon analogues
CA2853884A1 (en) 2011-11-03 2013-05-10 Zealand Pharma A/S Glp-1 receptor agonist peptide gastrin conjugates
SG11201403377QA (en) * 2011-12-23 2014-07-30 Zealand Pharma As Glucagon analogues
WO2013164483A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
MY170671A (en) 2012-07-23 2019-08-26 Zealand Pharma As Glucagon analogues
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CA2891931A1 (en) * 2012-11-20 2014-05-30 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
WO2014096179A1 (en) * 2012-12-19 2014-06-26 Novo Nordisk A/S Novel glp-1 receptor agonists with cholesterol efflux activity
SG10201705097PA (en) 2012-12-21 2017-07-28 Sanofi Sa Functionalized exendin-4 derivatives
PL2986313T3 (pl) 2013-04-18 2019-12-31 Novo Nordisk A/S Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
US9988429B2 (en) * 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
SI3057984T1 (sl) * 2013-10-17 2018-10-30 Zealand Pharma A/S Acilirani glukagonski analogi
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
US10093713B2 (en) * 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
CN103724424B (zh) * 2013-12-27 2015-05-27 浙江省农业科学院 一种mPEG-SPA-pGLP-2复合物及其制备方法和应用
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
JP2017536343A (ja) * 2014-10-10 2017-12-07 ノヴォ ノルディスク アー/エス 安定したglp−1ベースのglp−1/グルカゴン受容体コアゴニスト
TWI705973B (zh) 2014-10-29 2020-10-01 丹麥商西蘭製藥公司 Gip促效劑化合物及方法
TN2017000271A1 (en) * 2014-12-30 2018-10-19 Hanmi Pharm Ind Co Ltd Glucagon derivative having improved stability
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
WO2016168388A2 (en) * 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
TWI707867B (zh) 2015-04-16 2020-10-21 丹麥商西蘭製藥公司 醯化之昇糖素類似物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TN2017000555A1 (en) 2015-06-30 2019-04-12 Hanmi Pharm Ind Co Ltd Glucagon derivative and a composition comprising a long acting conjugate of the same
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
PH12018501409B1 (en) 2015-12-31 2023-03-10 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
EP3888667B1 (en) 2016-06-09 2023-10-25 AmideBio LLC Glucagon analog and methods of use thereof
JP7208020B2 (ja) 2016-06-29 2023-01-18 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン誘導体、その結合体、及びそれを含む組成物、並びにその治療的用途
WO2018104561A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
CN116143939A (zh) * 2017-11-24 2023-05-23 浙江道尔生物科技有限公司 一种治疗代谢疾病的多重活性蛋白
CN120887972A (zh) * 2017-11-24 2025-11-04 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
CN111818971A (zh) 2018-01-03 2020-10-23 梅德瑞斯糖尿病有限责任公司 用于治疗nash和其他紊乱的改进的肽药物
WO2021083306A1 (zh) * 2019-10-31 2021-05-06 东莞市东阳光生物药研发有限公司 Glp-1/gcg双受体激动剂多肽
EP3842060A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
US20230174608A1 (en) * 2020-05-09 2023-06-08 Tianjin Institute Of Pharmaceutical Research Co., Ltd. Polypeptide Derivative Having Dual Receptor Agonistic Action and Use Thereof
CN117202924A (zh) 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
ATE366115T1 (de) * 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc Inotropische und diuretische effekte von exendin und glp-1
JP4394279B2 (ja) 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
WO2002034285A2 (en) * 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7192922B2 (en) * 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
WO2007100535A2 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation グルカゴン/glp−1受容体コアゴニスト
DK2158214T3 (da) * 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
AU2009260302B2 (en) 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation 生理学的pHの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
US20100240883A1 (en) * 2009-03-18 2010-09-23 Nian Wu Lipid-drug conjugates for drug delivery
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物

Similar Documents

Publication Publication Date Title
JP2013517307A5 (enExample)
US10253080B2 (en) Glucagon-like-peptide-2 (GLP-2) analogues
AU2011206979B2 (en) Treatment of cardiac conditions
JP6023048B2 (ja) グルカゴン類似体
CN104662038B (zh) 胰高血糖素类似物
US9765131B2 (en) Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
JP2015517459A5 (enExample)
JP2015524419A5 (enExample)
RU2017112738A (ru) Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
JP2017533194A5 (enExample)
JP2018506507A5 (enExample)
JP2013543853A5 (enExample)
JP2014529629A5 (enExample)
JP2012532898A (ja) アシル化グルカゴン類似体
JP2014504597A (ja) アシル化グルカゴン類似体とインスリン類似体の組合せ物
EP2025684A1 (en) Glucagon analogues
JP2013523618A5 (enExample)
JP2014501712A5 (enExample)
JP2015502918A5 (enExample)
WO2011134284A1 (zh) 胰高血糖素样肽-1类似物及其应用
US9200053B2 (en) Insulin analogues containing penta-fluoro-Phenylalanine at position B24
CA3073011C (en) Acylated oxyntomodulin peptide analog
JPWO2021239082A5 (enExample)
CN104918954A (zh) N-末端电荷发生变化的胰岛素分泌肽衍生物
JP2014205708A5 (enExample)